Roberto Gulminetti

IRCCS Fondazione Policlinico San Matteo

Emailr.gulminetti@smatteo.pv.it

705 Citations
16 h-Index

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Roberto Gulminetti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

47 Similar Profiles

HIV Medicine & Life Sciences

HIV-1 Medicine & Life Sciences

Hepacivirus Medicine & Life Sciences

Genotype Medicine & Life Sciences

Virus Diseases Medicine & Life Sciences

Antiviral Agents Medicine & Life Sciences

Ritonavir Medicine & Life Sciences

Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1991 2019

705 Citations
16 h-Index
55 Article

Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine: Data from the SCOLTA project

Bagella, P., Squillace, N., Ricci, E., Gulminetti, R., De Socio, G. V., Taramasso, L., Pellicanò, G., Menzaghi, B., Celesia, B. M., Dentone, C., Orofino, G., Bonfanti, P. & Madeddu, G., Jan 1 2019, In : Infection and Drug Resistance. 12, p. 1385-1391 7 p.

Research output: Contribution to journal › Article

Open Access

Lipids

Protease Inhibitors

Reverse Transcriptase Inhibitors

Triglycerides

HDL Cholesterol

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

DAU Study Group, Jun 1 2019, In : AIDS (London, England). 33, 7, p. 1256-1260 5 p.

Research output: Contribution to journal › Article

Viral Load

HIV-1

Reverse Transcriptase Inhibitors

Cardiovascular Diseases

HIV

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

Paolucci, S., Novazzi, F., Piralla, A., Maserati, R., Gulminetti, R., Novati, S., Barbarini, G., Sacchi, P., Fratini, A., Bellotti, L. & Baldanti, F., Jan 1 2019, In : Infection and Drug Resistance. 12, p. 1975-1984 10 p.

Research output: Contribution to journal › Article

Open Access

Hepacivirus

Antiviral Agents

Genotype

RNA

Treatment Failure

5 Citations (Scopus)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

on behalf of CISAI Study Group, Jul 31 2018, In : BMC Infectious Diseases. 18, 1, 357.

Research output: Contribution to journal › Article

Rilpivirine

efavirenz

Integrase Inhibitors

Ritonavir

Protease Inhibitors

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., De Socio, G. V., Martinelli, C., Gulminetti, R., Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, P., Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., Stagno, A. & 26 others, Mazzotta, F., Penco, G., Cassola, G., Nicolini, L. A., Dentone, C., Molteni, C., Palvarini, L., Scalzini, A., Carenzi, L., Rizzardini, G., Valsecchi, L., Cordier, L., Rusconi, S., Colombo, V., Galli, M., Franzetti, M., Sgrelli, A., Mazzotta, E., Parruti, G., Bagella, P., Mura, M. S., Libertone, R., Antinori, A., Di Giambenedetto, S., Guastavigna, M. & Caramello, P., Jul 31 2018, In : BMC Infectious Diseases. 18, 1, p. 357

Research output: Contribution to journal › Article